Equivalent of Form PTO/SB/08A (07-05)
Approved for use through 07/31/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 5

Complete if Known	
Application Number	10/553,685 *(Natl. Phase of PCT/US2004/008323)*
Filing Date	§371 Date: November 1, 2006
First Named Inventor	MI, Sha
Art Unit	1656
Examiner Name	CARLSON, Karen C.
Attorney Docket Number	2159.0440003/EJH/CLD

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/KCC/	US22	4,444,887	04-24-1984	Michael K. Hoffman	
	US23	4,694,778	09-22-1987	Learn *et al.*	
	US24	4,716,111	12-29-1987	Osband *et al.*.	
	US25	4,816,397	03-28-1989	Boss *et al.*	
	US26	4,816,567	03-28-1989	Cabilly *et al.*	
	US27	4,946,778	08-07-1990	Ladner *et al.*	
	US28	5,122,464	06-16-1992	Wilson *et al.*	
	US29	5,223,409	06-29-1993	Ladner *et al.*.	
	US30	5,225,539	07-06-1993	Gregory P. Winter	
	US31	5,258,498	11-02-1993	Huston *et al.*	
	US32	5,314,995	05-24-1997	Fell, Jr., *et al.*	
	US33	5,403,484	04-04-1995	Ladner *et al.*	
	US34	5,413,923	05-09-1995	Kucherlapati *et al.*	
	US35	5,427,908	06-27-1995	Dower *et al.*	
	US36	5,516,637	05-14-1996	Huang *et al.*	
	US37	5,530,101	06-25-1996	Queen *et al.*	
	US38	5,545,806	08-13-1996	Lonberg *et al.*	
	US39	5,565,332	10-15-1996	Hoogenboom *et al.*	
	US40	5,569,825	10-29-1996	Lonberg *et al.*	
	US41	5,571,698	11-05-1996	Ladner *et al.*	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T[6]
	FP24	WO 88/09810 A1	12-15-1988	Synthetic Genetics	
	FP25	WO 89/01036 A1	02-09-1989	Celltech Limited	
	FP26	WO 89/10134 A1	11-02-1989	The Regents of the Univ. of CA	
	FP27	WO 89/12624 A2	12-28-1989	Cetus Corporation	
	FP28	WO 90/02809 A1	03-22-1990	Protein Engineering Corp.	
	FP29	WO 90/11364 A1	10-04-1990	University Patents, Inc.	
	FP30	WO 91/09967 A1	07-11-1991	Celltech Limited	
	FP31	WO 91/10737 A1	07-25-1991	Molecular Affinities Corp.	
	FP32	WO 91/10741 A1	07-25-1991	Cell Genesys, Inc.	
	FP33	WO 91/14438 A1	10-03-1991	Trustees of Columbia Univ. in the City of NY	
/KCC/	FP34	WO 92/01047 A1	01-23-1992	Cambridge Antibody Tech., Ltd.	

Examiner Signature	/Karen Cochrane Carlson/ (11/19/2008)	Date Considered	

846353_1.DOC

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Equivalent of Form PTO/SB/08A (07-05)
Approved for use through 07/31/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				*Complete if Known*	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*				Application Number	10/553,685 *(Natl. Phase of PCT/US2004/008323)*
				Filing Date	§371 Date: November 1, 2006
				First Named Inventor	MI, Sha
				Art Unit	1656
				Examiner Name	CARLSON, Karen C.
Sheet	2	of	5	Attorney Docket Number	2159.0440003/EJH/CLD

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/KCC/	US42	5,574,009	11-12-1996	Cohen *et al.*	
	US43	5,580,717	12-03-1996	Dower *et al.*	
	US44	5,585,089	12-17-1996	Queen *et al.*	
	US45	5,589,369	12-31-1996	Seidman *et al.*	
	US46	5,625,126	04-29-1997	Lonberg *et al.*	
	US47	5,633,425	05-27-1997	Lonberg *et al.*	
	US48	5,658,570	08-19-1997	Newman *et al.*	
	US49	5,658,727	08-19-1997	Barbas *et al.*	
	US50	5,661,016	08-26-1997	Lonberg *et al.*	
	US51	5,693,761	12-02-1997	Queen *et al.*	
	US52	5,693,762	12-02-1997	Queen *et al.*	
	US53	5,693,780	12-02-1997	Newman *et al.*	
	US54	5,698,426	12-16-1997	William D. Huse	
	US55	5,725,859	03-10-1998	Omer	
	US56	5,733,743	03-31-1998	Johnson *et al.*	
	US57	5,750,753	05-12-1998	Kimae *et al.*	
	US58	5,756,096	05-26-1998	Newman *et al.*	
	US59	5,772,997	06-30-1998	Hudziak *et al.*	
	US60	5,780,225	07-14-1998	Wigler *et al.*	
	US61	5,807,715	09-15-1998	Morrison *et al.*	
	US62	5,811,524	09-22-1998	Brams *et al.*	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T[6]
	FP35	WO 92/08495 A1	05-29-1992	Abbott Biotech, Inc.	
	FP36	WO 92/18619 A1	10-29-1992	The Scripps Research Inst.	
	FP37	EP 0 519 596 A1	12-23-1992	Merck & Co. Inc.	
	FP38	WO 92/22324 A1	12-23-1992	Xoma Corporation	
	FP39	WO 93/11236 A1	06-10-1993	Medical Research Council; Cambridge Antibody Technology Ltd.	
	FP40	EP 0 396 387 B1	12-22-1993	Research Development Foundation	
	FP41	EP 0 368 684 B1	03-09-1994	Medical Research Council	
	FP42	WO 94/09817 A1	05-11-1994	City of Hope	
/KCC/	FP43	EP 0 239 400 B1	08-03-1994	Medical Research Council	

Examiner Signature	/Karen Cochrane Carlson/ (11/19/2008)	Date Considered	

846353_1.DOC

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Equivalent of Form PTO/SB/08A (07-05)
Approved for use through 07/31/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 5

Complete if Known	
Application Number	10/553,685 *(Natl. Phase of PCT/US2004/008323)*
Filing Date	§371 Date: November 1, 2006
First Named Inventor	MI, Sha
Art Unit	1656
Examiner Name	CARLSON, Karen C.
Attorney Docket Number	2159.0440003/EJH/CLD

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/KCC/	US63	5,814,318	09-29-1998	Lonberg *et al.*	
	US64	5,821,047	10-13-1998	Garrard *et al.*	
	US65	5,837,821	11-17-1998	Anna M. Wu	
	US66	5,892,019	04-06-1999	Schlom *et al.*	
	US67	5,914,237	06-22-1999	Godowski *et al.*	
	US68	5,939,598	08-17-1999	Kucherlapati *et al.*	
	US69	5,969,108	10-19-1999	McCafferty *et al.*	
	US70	6,025,145	02-15-2000	Godowski *et al.*	
	US71	6,054,561	04-25-2000	Ring	
	US72	6,075,181	06-13-2000	Kucherlapati *et al.*	
	US73	6,150,584	11-21-2000	Kucherlapati *et al.*	
	US74	6,159,730	12-12-2000	Mitchell E. Reff	
	US75	6,180,370 B1	10-30-2001	Queen *et al.*	
	US76	6,280,964 B1	08-28-2001	Kavanaugh *et al.*	
	US77	6,333,169 B1	12-25-2001	Hudziak *et al.*	
	US78	6,387,371 B1	05-14-2002	Hudziak *et al.*	
	US79	6,399,063 B1	06-04-2002	Hudziak *et al.*	
	US80	6,413,777 B1	07-02-2002	Reff *et al.*	
	US81	6,420,140 B1	07-16-2002	Hori *et al.*	
	US82	6,458,592 B1	10-01-2002	Jakobovits *et al.*	
	US83	6,696,290 B2	02-24-2004	Fitzpatrick *et al.*	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T[6]
	FP44	WO 95/15982 A2	06-15-1995	Genzyme Corporation	
	FP45	WO 95/20401 A1	08-03-1995	Trustees of Boston Univ.	
	FP46	EP 0 401 384 B1	03-13-1996	Kirin-Amgen Inc.	
	FP47	WO 96/33735 A1	10-31-1996	Cell Genesys, Inc.	
	FP48	WO 96/34096 A1	10-31-1996	Cell Genesys, Inc.	
	FP49	WO 97/00271 A1	01-03-1997	The Regents of the University of California	
	FP50	WO 98/16654 A1	04-23-1998	Japan Tobacco, Inc.; Abgenix, Inc.	
	FP51	WO 98/24893 A2	06-11-1998	Abgenix, Inc.	
/KCC/	FP52	WO 98/46645 A2	10-22-1998	Peter KUFER	

Examiner Signature	/Karen Cochrane Carlson/ (11/19/2008)	Date Considered	

846353_1.DOC

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Equivalent of Form PTO/SB/08A (07-05)
Approved for use through 07/31/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 5

Complete if Known	
Application Number	10/553,685 *(Natl. Phase of PCT/US2004/008323)*
Filing Date	§371 Date: November 1, 2006
First Named Inventor	MI, Sha
Art Unit	1656
Examiner Name	CARLSON, Karen C.
Attorney Docket Number	2159.0440003/EJH/CLD

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/KCC/	US84	6,949,245 B1	09-27-2005	Sliwkowski	
	US85	6,987,088 B1	01-17-2006	Dennis	
	US86	7,098,302 B1	08-29-2006	Krag *et al.*	
	US87	7,223,558 B1	05-29-2007	Wu *et al.*	
	US88	2002/0004587 A1	01-10-2002	Miller *et al.*	
	US89	2002/0182671 A1	12-05-2002	Lal Preeti *et al.*	
	US90	2004/0005579 A1	01-08-2004	Birse *et al.*	
	US91	2005/0153396 A1	07-14-2005	Baker *et al.*	
	US92	2006/0034840 A1	02-16-2006	Agus *et al.*	
	US93	2006/0088523 A1	04-27-2006	Andya *et al.*	
	US94	2007/0071675 A1	03-29-2007	Wu *et al.*	
	US95	2007/0083334 A1	04-12-2007	Mintz *et al.*	
	US96	2007/0105122 A1	05-10-2007	Ota *et al.*	
	US97	2007/0274918 A1	11-29-2007	Mosyak *et al.*	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T[6]
	FP53	WO 98/050433 A2	11-12-1998	Abgenix, Inc.	
	FP54	WO 98/52976 A1	11-26-1998	Biovation Limited	
	FP55	WO 00/34317 A2	06-15-2000	Biovation Ltd.	
	FP56	WO 00/58473 A2	10-05-2000	Curagen Corp.	
	FP57	WO 01/055333 A2	08-02-2001	Hyseq Inc.	
	FP58	WO 01/55317 A2	08-02-2001	Human Genome Sciences Inc.	
	FP59	WO 01/59063 A2	08-16-2001	Human Genome Sciences Inc.	
	FP60	WO 02/060955 A2	08-08-2002	IDEC Pharmaceuticals Corp.	
	FP61	WO 02/096948 A2	12-05-2002	IDEC Pharmaceuticals Corp.	
	FP62	EP 0 058 481 B2	05-21-2003	Astra Zeneca AB	
/KCC/	FP63	WO 03/061559 A2	07-31-2003	University of Vermont and State Agricultural	

Examiner Signature	/Karen Cochrane Carlson/ (11/19/2008)	Date Considered	

846353_1.DOC

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Equivalent of Form PTO/SB/08A (07-05)
Approved for use through 07/31/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 5

Complete if Known	
Application Number	10/553,685 *(Natl. Phase of PCT/US2004/008323)*
Filing Date	§371 Date: November 1, 2006
First Named Inventor	MI, Sha
Art Unit	1656
Examiner Name	CARLSON, Karen C.
Attorney Docket Number	2159.0440003/EJH/CLD

				Collge	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T[6]
/KCC/	FP64	EP 0 592 106 B1	11-24-2004	Immunogen Inc.	
	FP65	WO 2006/002437 A2	01-05-2006	Biogen Idec MA Inc.	
	FP66	WO 2006/119013 A2	11-09-2006	Wyeth; King's College London	
	FP67	WO 2006/136006 A1	12-28-2006	McGill University	
	FP68	WO 2007/008547 A2	01-18-2007	Biogen Idec MA Inc.	
/KCC/	FP69	WO 2008/013782 A2	01-31-2008	Biogen Idec MA Inc.	

846353v1

Examiner Signature	/Karen Cochrane Carlson/ (11/19/2008)	Date Considered	

846353_1.DOC

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Equivalent of Form PTO/SB/08b (01-08)
Approved for use through 05/31/2008
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				***Complete if Known***	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*				Application Number	10/553,685 *(Natl. Phase of PCT/US2004/008323)*
				Filing Date	§371 Date: November 1, 2006
				First Named Inventor	MI, Sha
				Art Unit	1656
				Examiner Name	CARLSON, Karen C.
Sheet	1	of	7	Attorney Docket Number	2159.0440003/EJH/CLD

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
/KCC/	NPL33	Battaglia, G., *et al.*, "Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice," *Neuropharmacol. 45*:155-166, Elsevier Science Ltd. (2003)	
	NPL34	Baulida, J., *et al.*, "All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired," *J. Biol. Chem. 271*:5251-5257, The American Society for Biochemistry and Molecular Biology, Inc. (1996)	
	NPL35	Baulida, J. and Carpenter, G., "Heregulin Degradation in the Absence of Rapid Receptor-Mediated Internalization," *Exp. Cell Res. 232*:167-172, Academic Press (1997)	
	NPL36	Baumann, N., *et al.*, "Biology of Oligodendrocyte and Myelin in the Mammalian Central Nervous System," *J. Physiol. Rev.* 81:871-927, American Physiological Society (2001)	
	NPL37	Blum, M., "A null mutation in TGF-α leads to a reduction in midbrain dopaminergic neurons in the substantia nigra," *Nat. Neurosci. 1*:374-377, Nature Publishing Group (1998)	
	NPL38	Brundin, P., *et al.*, "The rotating 6-hydroxydopamine-lesioned mouse as a model for assessing functional effects of neuronal grafting," *Brain Res. 366*:346-349, Elsevier Publishers B.V. (1986)	
	NPL39	Chang, A., *et al.*, "Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis," *N. Engl. J. Med.* 346:165-173, Massachusetts Medical Society (2002)	
	NPL40	Citri, A., *et al.*, "The deaf and the dumb: The biology of ErbB-2 and ErbB-3," *Exp. Cell Res. 284*:54-65, Elsevier Science (2003)	
	NPL41	Cohen, S., *et al.*, "Nonchromosomal Antibiotic Resistance in Bacteria: Genetic Transformation of *Escherichia coli* by R-Factor DNA," *Proc. Natl. Acad. Sci. USA* 69:2110-2114 (1972)	
/KCC/	NPL42	Csordás, G., *et al*,. "Sustained Down-regulation of the Epidermal Growth Factor Receptor by Decorin," *J. Biol. Chem. 275*:32879-32887, The American Society for Biochemistry and Molecular Biology, Inc. (2000)	

Examiner Signature	/Karen Cochrane Carlson/ (11/19/2008)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Equivalent of Form PTO/SB/08b (01-08)
Approved for use through 05/31/2008
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				***Complete if Known***	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*				Application Number	10/553,685 *(Natl. Phase of PCT/US2004/008323)*
				Filing Date	§371 Date: November 1, 2006
				First Named Inventor	MI, Sha
				Art Unit	1656
				Examiner Name	CARLSON, Karen C.
Sheet	2	of	7	Attorney Docket Number	2159.0440003/EJH/CLD

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T[2]
/KCC/	NPL43	Eby, M.T., *et al.*, "TAJ, a Novel Member of the Tumor Necrosis Factor Receptor Family, Activates the c-Jun N-terminal Kinase Pathway and Mediates Caspase-independent Cell Death," *J. Biol. Chem. 275*:15336-15342, The American Society for Biochemistry and Molecular Biology, Inc. (2000)	
	NPL44	Fendly, B.M., *et al.*, "The Extracellular Domain of HER2/neu Is a Potential Immunogen for Active Specific Immunotherapy of Breast Cancer," *J. Biol. Resp. Mod. 9*:449-455, Raven Press Ltd. (1990)	
	NPL45	Fu, Q.-L., *et al.*, "Blocking LINGO-1 Function Promotes Retinal Ganglion Cell Survival Following Ocular Hypertension and Optic Nerve Transection," *Invest. Ophthal. Vis. Sci. 49*:975-985, Association for Research in Vision and Ophthalmology (March 2008)	
	NPL46	Fuxe, K. and Ungerstedt, U., "Antiparkinsonian Drugs and Dopaminergic Neostriatal Mechanisms: Studies in Rats with Unilateral 6-Hydroxydopamine (=6-OH-DA)-Induced Degeneration of the Nigro-Neostriatal DA Pathway and Quantitative Recording of Rotational Behaviour," *Pharmac. Ther. B*:41-47, Pergamon Press (1976)	
	NPL47	Ghiglione, C., *et al.*, "The Transmembrane Molecule Kekkon 1 Acts in a Feedback Loop to Negatively Regulate the Activity of the *Drosophila* EGF Receptor during Oogenesis," *Cell 96*:847-856, Cell Press (1999)	
	NPL48	Gill, S.S., *et al.*, "Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease," *Nat. Med. 9*:589-595, Nature Publishing Company (2003)	
	NPL49	Gill, S.S., *et al.*, "Addendum: Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease," *Nat. Med. 12*:479, Nature Publishing Company (April 2006)	
	NPL50	Gille, G., *et al.*, "Oxidative Stress to Dopaminergic Neurons as Models of Parkinson's Disease," *Ann. N.Y. Acad. Sci. 1018*:533-540, New York Academy of Sciences (June 2004)	
	NPL51	Gur, G., *et al.*, "LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation," *EMBO J. 23*:3270-3281, Oxford University Press (August 2004)	
/KCC/	NPL52	Ha, H., *et al.*, "Membrane Rafts Play a Crucial Role in Receptor Activator of Nuclear Factor κB Signaling and Osteoclast Function," *J. Biol. Chem. 278*:18573-18580, The American Society for Biochemistry and Molecular Biology, Inc. (2003)	

Examiner Signature	/Karen Cochrane Carlson/ (11/19/2008)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Equivalent of Form PTO/SB/08b (01-08)
Approved for use through 05/31/2008
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				***Complete if Known***	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*				Application Number	10/553,685 *(Natl. Phase of PCT/US2004/008323)*
				Filing Date	§371 Date: November 1, 2006
				First Named Inventor	MI, Sha
				Art Unit	1656
				Examiner Name	CARLSON, Karen C.
Sheet	3	of	7	Attorney Docket Number	2159.0440003/EJH/CLD

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T[2]
/KCC/	NPL53	Harwerth, I.-M., *et al.*, "Monoclonal Antibodies against the Extracellular Domain of the erbB-2 Receptor Function as Partial Ligand Agonists," *J. Biol. Chem. 267*:15160-15167, The American Society for Biochemistry and Molecular Biology, Inc. (1992)	
	NPL54	Hoet, R.M., *et al.*, "Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity," *Nat. Biotechnol. 23*:344-348, Nature America Publishing (March 2005)	
	NPL55	Isacson, O., "Problems and Solutions for Circuits and Synapses in Parkinson's Disease," *Neuron 43*:165-168, Cell Press (July 2004)	
	NPL56	Kim, J.Y., *et al.*, "The Role of ErbB2 Signaling in the Onset of Terminal Differentiation of Oligodendrocytes *In Vivo*," *J. Neurosci. 23*:5561-5571, Society of Neuroscience (2003)	
	NPL57	Klapper, L.N., *et al.*, "A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors," *Oncogene 14*:2099-2109, Nature Publishing Company (1997)	
	NPL58	Knappik, A., *et al.*, "Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucloetides," *J. Mol. Biol. 296*:57-86, Academic Press (2000)	
	NPL59	Kolodny, E.H., "Dysmyelinating and demyelinating conditions in infancy," *Curr. Opin. Neurol. Neurosurg. 6*:379-386, Current Science (1993)	
	NPL60	Kornilova, E., *et al.*, "Lysosomal Targeting of Epidermal Growth Factor Receptors via a Kinase-dependent Pathway Is Mediated by the Receptor Carboxyl-terminal Residues 1022-1123," *J. Biol. Chem. 271*:30340-30346, The American Society for Biochemistry and Molecular Biology, Inc. (1996)	
	NPL61	Laederich, M.B., *et al.*, "The Leucine-rich Repeat Protein LRIG1 Is a Negative Regulator of ErbB Family Receptor Tyrosine Kinases," *J. Biol. Chem. 279*:47050-47056, The American Society for Biochemistry and Molecular Biology, Inc. (November 2004)	
/KCC/	NPL62	Laederich, M.B., *et al.*, "The Leucine-rich Repeat Protein LRIG1 Is a Negative Regulator of ErbB Family Receptor Tyrosine Kinases," *J. Biol. Chem. 279*:52806, The American Society for Biochemistry and Molecular Biology, Inc. (December 2004)	

Examiner Signature	/Karen Cochrane Carlson/ (11/19/2008)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Equivalent of Form PTO/SB/08b (01-08)
Approved for use through 05/31/2008
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				***Complete if Known***	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*				Application Number	10/553,685 *(Natl. Phase of PCT/US2004/008323)*
				Filing Date	§371 Date: November 1, 2006
				First Named Inventor	MI, Sha
				Art Unit	1656
				Examiner Name	CARLSON, Karen C.
Sheet	4	of	7	Attorney Docket Number	2159.0440003/EJH/CLD

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T[2]
/KCC/	NPL63	Li, S., *et al.*, "Blockade of Nogo-66, Myelin-Associated Glycoprotein, and Oligodendrocyte Myelin Glycoprotein by Soluble Nogo-66 Receptor Promotes Axonal Sprouting and Recovery after Spinal Injury," *J. Neurosci. 24*:10511-10520, Society of Neuroscience (November 2004)	
	NPL64	Lin, L., *et al.*, "Netrin-1 and slit-2 regulate and direct neurite growth of ventral midbrain dopaminergic neurons," *Molec. Cell. Neurosci. 28*:547-555, Elsevier Inc. (March 2005)	
	NPL65	Ma, L., *et al.*, "Ligand-Dependent Recruitment of the ErbB4 Signaling Complex into Neuronal Lipid Rafts," *J. Neurosci. 23*:3164-3175, Society of Neuroscience (2003)	
	NPL66	Messier, C., *et al.*, "New Techniques in Stereotaxic Surgery and Anesthesia in the Mouse," *Pharmacol. Biochem. Behav. 63*:313-318, Elsevier Science Inc. (1999)	
	NPL67	Mi, S., *et al.*, "LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis," *Nat. Med. 13*:1228-1233, Nature Publishing Group (October 2007)	
	NPL68	Morell, P., *et al.*, "Gene Expression in Brain during Cuprizone-Induced Demyelination and Remyelination," *Molec. Cell. Neurosci. 12*:220-227, Academic Press (1998)	
	NPL69	Nagy, P., *et al.*, "Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2," *J. Cell Sci. 115*:4251-4262, The Company of Biologists Ltd. (2002)	
	NPL70	Nagy, Z.A., *et al.*, "Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells," *Nat. Med. 8*:801-807, Nature Publishing Group (2002)	
	NPL71	Orlandi, R., *et al.*, "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," *Proc. Natl. Acad. Sci. USA 86*:3833-3837, National Academy of Sciences (1989)	
/KCC/	NPL72	Park, S.-K., *et al.*, "The erbB2 gene is required for the development of terminally differentiated spinal cord oligodendrocytes," *J. Cell Biol. 154*:1245-1258, The Rockefeller University Press (2001)	

Examiner Signature	/Karen Cochrane Carlson/ (11/19/2008)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Equivalent of Form PTO/SB/08b (01-08)
Approved for use through 05/31/2008
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				***Complete if Known***	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*				Application Number	10/553,685 *(Natl. Phase of PCT/US2004/008323)*
				Filing Date	§371 Date: November 1, 2006
				First Named Inventor	MI, Sha
				Art Unit	1656
				Examiner Name	CARLSON, Karen C.
Sheet	5	of	7	Attorney Docket Number	2159.0440003/EJH/CLD

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T[2]
/KCC/	NPL73	Park, J.B., *et al.*, A TNF Receptor Family Member, TROY, is a Coreceptor with Nogo Receptor in Mediating the Inhibitory Activity of Myelin Inhibitors," Erratum in *Neuron* 3:815, Elsevier Inc. (March 2005)	
	NPL74	Pinkas-Kramarski, R., *et al.*, "Neu Differentiation Factor/Neuregulin Isoforms Activate Distinct Receptor Combinations," *J. Biol. Chem. 271*:19029-19032, The American Society for Biochemistry and Molecular Biology, Inc. (1996)	
	NPL75	Plant, G.W., *et al.*, "Purified Adult Ensheathing Glia Fail to Myelinate Axons under Culture Conditions that Enable Schwann Cells to Form Myelin," *J. Neurosci. 22*:6083-6091, Society for Neuroscience (2002)	
	NPL76	Qiu, X.-B. and Goldberg, A.L., "Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3," *Proc. Natl. Acad. Sci. USA 99*:14843-14848, National Academy of Sciences (2002)	
	NPL77	Rauchenberger, R., *et al.*, "Human Combinatorial Fab Library Yielding Specific and Functional Antibodies against the Human Fibroblast Growth Factor Receptor 3," *J. Biol. Chem. 278*:38194-38205, The American Society for Biochemistry and Molecular Biology, Inc. (2003)	
	NPL78	Rubinson, D.A., *et al.*, "A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference," *Nat. Genet.* 33:401-406, Nature Publishing Group (2003)	
	NPL79	Schmucker, J., *et al.*, "erbB3 Is Dispensable for Oligodendrocyte Development *In Vitro* and *In Vivo*," *Glia 44*:67-75, Wiley-Liss, Inc. (2003)	
	NPL80	Shah, B.H., *et al.*, "Role of EGF Receptor Transactivation in Phosphoinositide 3-Kinase-Dependent Activation of MAP Kinase by GPCRs," *J. Cell. Physiol. 206*:47-57, Wiley-Liss Inc. (January 2006)	
	NPL81	Stolt, C.C., *et al.*, "Terminal differentiation of myelin-forming oligodendrocytes depends on the transcription factor Sox10," *Genes & Dev. 16*:165-170, Cold Spring Harbor Laboratory Press (2002)	
/KCC/	NPL82	Sussman, C.R., *et al.*, "The ErbB4 Neurogulin Receptor Mediates Suppression of Oligodendrocyte Maturation," *J. Neurosci. 25*:5757-5762, Society for Neuroscience (June 2005)	

Examiner Signature	/Karen Cochrane Carlson/ (11/19/2008)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Equivalent of Form PTO/SB/08b (01-08)
Approved for use through 05/31/2008
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				***Complete if Known***	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*				Application Number	10/553,685 *(Natl. Phase of PCT/US2004/008323)*
				Filing Date	§371 Date: November 1, 2006
				First Named Inventor	MI, Sha
				Art Unit	1656
				Examiner Name	CARLSON, Karen C.
Sheet	6	of	7	Attorney Docket Number	2159.0440003/EJH/CLD

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T[2]
/KCC/	NPL83	Trapp, B.D., *et al.*, "Pathogenesis of tissue injury in MS lesions," *J. Neuroimmunol. 98*:49-56, Elsevier Science B.V. (1999)	
	NPL84	Trapp, B.D., *et al.*, "Axonal pathology in multiple sclerosis: relationship to neurologic disability," *Curr. Opin. Neurol. 12*:295-302, Lippincott Williams & Wilkins (1999)	
	NPL85	Tzahar, E., *et al.*, "Bivalence of EGF-like ligands drives the ErbB signaling network," *EMBO J. 16*:4938-4950, Oxford University Press (1997)	
	NPL86	Vartanian, T., *et al.*, "Failure of spinal cord oligodendrocyte development in mice lacking neuregulin," *Proc. Natl. Acad. Sci. USA 96*:731-735, National Academy of Sciences (1999)	
	NPL87	Williams, E.-J. and Doherty, P., "Evidence for and against a Pivotal Role of PI 3-Kinase in a Neuronal Cell Survival Pathway," *Molec. Cell. Neurosci. 13*:272-280, Academic Press (1999)	
	NPL88	Xu, W., *et al.*, "Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu," *Proc. Natl. Acad. Sci. USA 99*:12847-12852, National Academy of Sciences (2002)	
	NPL89	Yang, L., *et al.*, "A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities," *Exp. Neurol. 191*:86-93, Elsevier Inc. (January 2005)	
	NPL90	Zhou, P., *et al.*, "ErbB2 Degradation Mediated by the Co-chaperone Protein CHIP," *J. Biol. Chem. 278*:13829-13837, The American Society for Biochemistry and Molecular Biology, Inc. (2003)	
	NPL91	NCBI Entrez, Accession No. AY324322, (first available May 4, 2004; last updated May 4, 2004)	
/KCC/	NPL92	International Search Report for International Application No. PCT/US2004/008323, mailed on October 15, 2004, European Patent Office, Rijswijk, Netherlands	

Examiner Signature	/Karen Cochrane Carlson/ (11/19/2008)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Equivalent of Form PTO/SB/08b (01-08)
Approved for use through 05/31/2008
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				***Complete if Known***	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*				Application Number	10/553,685 *(Natl. Phase of PCT/US2004/008323)*
				Filing Date	§371 Date: November 1, 2006
				First Named Inventor	MI, Sha
				Art Unit	1656
				Examiner Name	CARLSON, Karen C.
Sheet	7	of	7	Attorney Docket Number	2159.0440003/EJH/CLD

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T[2]
/KCC/	NPL93	United States Patent Application No. 11/892,036, inventors Mi, *et al.*, continuation of PCT/US2006/026271, international filing date of July 7, 2006 (NOT PUBLISHED)	
/KCC/	NPL94	United States Patent Application No. 12/092,662, inventors Mi, *et al.*, National Phase of PCT/US2006/042990, international filing date of November 3, 2006 (NOT PUBLISHED)	
/KCC/	NPL95	United States Patent Application No. 12/095,857, inventors Mi, *et al.*, National Phase of PCT/US2006/045993, international filing date of December 1, 2006 (NOT PUBLISHED)	

847113v1

Examiner Signature	/Karen Cochrane Carlson/ (11/19/2008)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.